Drug Profile
Radium-223 chloride - Bayer HealthCare
Alternative Names: AC1O4D1M; Alpharadin; ATI-BC-1; BAY88-8223; Ra-223; Radium Ra 233 dichloride; Radium-223; Radium-223 dichloride; Xofigo; XofigoRLatest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator Algeta
- Developer Algeta; Bayer HealthCare; Janssen; Medica Scientia Innovation Research; Royal Marsden NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; The Institute of Cancer Research; Thomas Jefferson University; University of Texas M. D. Anderson Cancer Center
- Class Analgesics; Antineoplastics; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bone metastases
- Phase III Prostate cancer
- Phase I/II Breast cancer; Non-small cell lung cancer
- No development reported Osteosarcoma; Renal cell carcinoma
- Discontinued Cancer pain; Multiple myeloma
Most Recent Events
- 08 Feb 2024 Bayer compltes a phase III trial in Bone metastases (from castration-resistant, chemotherapy-naive prostate cancer; first-line therapy, combination therapy) in US, Canada, the UK, Finland, Germany, Israel, Singapore, Spain, Norway, Italy, Sweden, Belgium, the Netherlands, Poland, Australia, Brazil, France and Japan (IV) (NCT02043678)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Bone metastases(In the elderly, Second-line therapy or greater, In adults) in Austria (IV, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Bone metastases(In the elderly, Second-line therapy or greater, In adults) in Finland (IV, Injection)